Immuno-oncology: new possibilities of drug therapy for solid tumors

Bolotina L.V.; Kaprin A.D.

doi:https://doi.org/10.17116/onkolog20176574-80

Close metadata

Recommended articles:

Efficacy of chemoimmunotargeted therapy in patients with advanced non-small cell lung cancer in real clinical practice. P.A. Herzen Journal of Oncology. 2025;(3):63-70

Possibilities of drug treatment for pseudomyxoma peritonei of appendiceal origin. P.A. Herzen Journal of Oncology. 2025;(6):59-64

Prognostically unfavorable types of breast cancer. P.A. Herzen Journal of Oncology. 2025;(6):78-82

mRNA cancer vaccines: features of problems and collisions. Molecular Genetics, Microbiology and Virology. 2025;(1):3-16

Application of T-cells with chimeric antigen receptor in the treatment of refractory autoimmune diseases. Russian Journal of Preventive Medicine. 2025;(7):106-110

Monoclonal antibodies in the treatment of recurrent polyposis rhinosinusitis. Literature review. Russian Bulletin of Otorhinolaryngology. 2025;(4):96-104

The impact of combined immunotherapy on the cellular composition of the tumor microenvironment in patients with gastric carcinoma. Russian Journal of Archive of Pathology. 2025;(4):24-30

Integrative principles of adaptive medical immunology in the treatment of secondary immunodeficiency: relevance of interdisciplinary interactions. Journal of Adaptive Medical Immunology and Public Health Issues. 2025;(1):6-20

Predictive immunotherapeutic markers of adenocarcinomas and adenosquamous carcinoma of the cervix. Russian Journal of Archive of Pathology. 2025;(5):74-79

Clinical efficacy of dupilumab monoclonal antibody in the treatment of recurrent severe chronic rhinosinusitis with nasal polyps without bronchial asthma. Russian Rhinology. 2025;(4):32-37

Abstract:

The paper presents current views on the mechanisms of immune responses in patients with malignant tumors, the interaction between tumor cells and immune system cells, and the ability of tumor cells to form protection mechanisms and provides information on novel drugs for solid tumors.

Keywords:

immune system

immunotherapy

immune response checkpoints

monoclonal antibodies

CTLA-4

PD-1

and PD-L1

Authors:

Bolotina L.V.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

SPIN RSCI: 2787-5414
Scopus AuthorID: 6603382243
ResearcherID: U-5441-2019
ORCID: 0000-0003-4879-2687

Kaprin A.D.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

SPIN RSCI: 1759-8101
Scopus AuthorID: 6602709853
ResearcherID: K-1445-2014
ORCID: 0000-0001-8784-8415

Close metadata

References:

DeVita VT Jr, Rosenberg SA. Two hundred years of cancer research. N Engl J Med. 2012;366(23):2207-2214. https://doi.org/10.1056/NEJMra1204479
Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J Clin. 2012;62(5):309-335. https://doi.org/10.3322/caac.20132
Surveillance, Epidemiology and End Results (SEER) Program. Available et: http://seer.cancer.gov
Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29:235-2371. https://doi.org/10.1146/annurev-immunol-031210-101324
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674. https://doi.org/10.1016/j.cell.2011.02.013
Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol. 2012;23(Suppl.8):viii6-viii9. https://doi.org/10.1093/annonc/mds256
Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 2004;4:11-22. https://doi.org/10.1038/nrc1252
Janeway CA, Travers P. Immunobiology: The immune system in health and disease. 6th ed. New York, NY: Garland Science; 2004.
Pardoll D. The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer. 2012;12:252-264. https://doi.org/10.1038/nrc3239
Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9(5):503-510. https://doi.org/10.1038/ni1582
Murphy K, Travers P, Walport M. Janeway’s immunobiology. 7th ed. New York, NY: Garland Science; 2008.
Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol. 2006;90:51-81. https://doi.org/10.1016/S0065-2776(06)90002-9.
Merelli B, Massi D, Cattaneo L, Mandalа M. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. Crit Rev Oncol Hematol. 2013;89(1):140-165. https://doi.org/10.1016/j.critrevonc.2013.08.002
Eggermont AM. Can immuno-oncology offer a truly pan-tumour approach to therapy? Ann Oncol. 2012;23(Suppl.8):viii53-viii57. https://doi.org/10.1093/annonc/mds264
Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbй C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-7420. https://doi.org/ 10.1158/1078-0432.CCR-09-1624
Hoos A. Evolution of end points for cancer immunotherapy trials. Ann Oncol. 2012;23(Suppl.8):viii47-viii52. https://doi.org/0.1093/annonc/mds263
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012:366(26):244-254. https://doi.org/10.1056/NEJMoa1200690
Ribas A, Chmielowski B, Glaspy JA. Do we need a different set of response assessment criteria for tumor immunotherapy? Clin Cancer Res. 2009;15(23):7116-7118. https://doi.org/10.1158/1078-0432.CCR-09-2376
Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM, Reck M. Overall survival and progression free survival results for a randomized phase 2 trial of Ipilimumab and Paclitaxel/ Carboplatin in first-line stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012;30(17):2046-2054. https://doi.org/10.1200/JCO.2011.38.4032
Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea SM, Dengel LT, Patterson JW, Slingluff CL Jr. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res. 2012;72(5):1070-1080. https://doi.org/10.1158/0008-5472.CAN-11-3218
Ruffini E, Asioli S, Filosso PL, Lyberis P, Bruna MC, Macrм L, Daniele L, Oliaro A. Clinical signiﬁcance of tumor-inﬁltrating lymphocytes in lung neoplasms. Ann Thorac Surg. 2009;87(2):356-372. https://doi.org/ 10.1016/j.athoracsur.2008.10.067
Tao H, Mimura Y, Aoe K, Kobayashi S, Yamamoto H, Matsuda E, Okabe K, Matsumoto T, Sugi K, Ueoka H. Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. Lung Cancer. 2012;75(1):95-101. https://doi.org/0.1016/j.lungcan.2011.06.002
Siddiqui SA, Frigola X, Bonne-Annee S, Mercader M, Kuntz SM, Krambeck AE, Sengupta S, Dong H, Cheville JC, Lohse CM, Krco CJ, Webster WS, Leibovich BC, Blute ML, Knutson KL, Kwon ED. Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clin Cancer Res. 2007;13(7):2075-2081. https://doi.org/10.1158/1078-0432.CCR-06-2139
Grosso JF, Horak CE, Inzunza D, et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538). J Clin Oncol. 2013;31(15,Suppl.1):abstr.3016.
Garon EB, Gandhi L, Rizviet N, et al. Antitumor activity of pembrolizumab (pembro; MK-3475) and correlation with programmed death ligand 1 (PD-L1) expression in a pooled analysis of patients (pts) with advanced non-small cell lung carcinoma (NSCLC). Ann Oncol. 2014;25(Suppl.5):v1-41. https://doi.org/10.1093/annonc/mdu438
Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889-1894. https://doi.org/10.1200/JCO.2014.56.2736
Robert C, Ribas A, Hamid O, et al. Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. In: ASCO Annual Meeting 2016. abstr.9503.
Brahmer JR, Rodriguez-Abreu D, Robinson AG, et al. Progression after the next line of therapy (PFS2) and updated OS among patients with advanced NSCLC and PD-L1 TPS ≥50% enrolled in KEYNOTE-024. In: LBA, ASCO Annual Meeting, 2017. abstr. 9000.
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D’Amico TA, DeCamp MM, Dilling TJ, Dobelbower M, Doebele RC, Govindan R, Gubens MA, Hennon M, Horn L, Komaki R, Lackner RP, Lanuti M, Leal TA, Leisch LJ, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. Non-small cell lung cancer. Version 5, 2017. NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(4):504-535.
Herbst RS, Baas P, Kim DW, Felip E, Pйrez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomized controlled trial. Lancet. 2016;387(10027):1540-1550. https://doi.org/10.1016/S0140-6736(15)01281-7
Herbst RS, Baas P, Kim D-W, et al. Factors associated with better overall survival in patients with previously treated, PD-L1-expressing advanced NSCLC: multivariate analysis of KEYNOTE-010. In: ASCO Annual Meeting, 2017. abstr. 9090.
Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L; KEYNOTE-021 investigators. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomized, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17(11):1497-1508. https://doi.org/10.1016/S1470-2045(16)30498-3
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P; CheckMate 025 Investigators. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803-1813. https://doi.org/10.1056/NEJMoa1510665
Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, Sedrak C, Jungbluth AA, Chua R, Yang AS, Roman RA, Rosner S, Benson B, Allison JP, Lesokhin AM, Gnjatic S, Wolchok JD. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925-931. https://doi.org/10.1056/NEJMoa1112824
Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134-144. https://doi.org/10.1056/NEJMoa1305133
Amos SM, Duong CPM, Westwood JA, Ritchie DS, Junghans RP, Darcy PK, Kershaw MH. Autoimmunity associated with immunotherapy of cancer. Blood. 2011;118:499-509. https://doi.org/10.1182/blood-2011-01-325266
Chow LQ. Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer. Am Soc Clin Oncol Educ Book. 2013:280-285. https://doi.org/10.1200/EdBook_AM.2013.33.e280
Parkhurst MR, Yang JC, Langan RC, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2011;19:620-626. https://doi.org/10.1038/mt.2010.272
Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood. 2010;116(19):3875-3886. https://doi.org/10.1182/blood-2010-01-265041
Ledezma B, Heng A. Real-world impact of education: treating patients with ipilimumab in a community practice setting Cancer Manag Res. 2014;6:5-14. https://www.drugs.com https://doi.org/10.2147/CMAR.S52543